Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Optimizing Metastatic Colorectal Cancer Care: From Clinical Evidence to Real-World Excellence : Episode 8
Real-World Evidence in mCRC: Special Populations and Safety Assessment
Panelists discuss how RWE informs treatment and safety decisions for special populations such as patients with ECOG PS 2 with metastatic colorectal cancer.
EP: 1.Overview of Available Third-Line Options in mCRC
EP: 2.Evidence Supporting FTD/TPI ± Bevacizumab in mCRC
EP: 3.Efficacy of Fruquintinib and Comparisons Across Agents in mCRC
EP: 4.Selecting Among Third-Line Therapies in Clinical Practice for mCRC
EP: 5.Leveraging Real-World Evidence in Sequencing Decisions for mCRC
EP: 6.Translating Real-World Outcomes in mCRC Into Patient Conversations
EP: 7.Incorporating Patient-Reported Outcomes in mCRC Into Shared Decision-Making
Now Viewing
EP: 8.Real-World Evidence in mCRC: Special Populations and Safety Assessment
Panelists note that patients with ECOG performance status (PS) 2 are underrepresented in clinical trials, making real-world data especially critical in guiding their care.
They highlight how emerging real-world evidence (RWE) provides insight into outcomes and tolerability for these vulnerable populations, supplementing limited trial evidence.
In addition, they discuss how real-world safety signals—sometimes distinct from clinical trials—must be carefully considered when determining treatment sequencing and monitoring approaches.
Related Videos
Related Content
